Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening, Construction, and Preliminary Evaluation of CLDN18.2-Specific Peptides for Noninvasive Molecular Imaging

21 Nov 2023

Abstract excerpt

Recent global clinical trials have shown that CLDN18.2 is an ideal target for the treatment of gastric cancer and that patients with high CLDN18.2 expression can benefit from targeted therapy. Therefore, accurate and comprehensive detection of CLDN18.2 expression is important for patient screening and guidance in anti-CLDN18.2 therapy. Phage display technology was used to screen CLDN18.2-specific peptides from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Nanoparticle-Based Drug Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38093841
DOI: 10.1021/acsptsci.3c00165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening, Construction, and Preliminary Evaluation of CLDN18.2-Specific Peptides for Noninvasive Molecular ImagingPMID 38093841Read ↗

Car-γδ T Cells Targeting Claudin18.2 Show Superior Cytotoxicity Against Solid Tumor Compared to Traditional Car-αβ T CellsSemantic proximity Read ↗

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentSemantic proximity Read ↗

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

SLP-76/LAT AND-gated CAR-T cells mediate highly specific and durable antitumor activity in pancreatic ductal adenocarcinoma with reduced gastric toxicitySemantic proximity Read ↗

Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer StrategiesSemantic proximity Read ↗

Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencingSemantic proximity Read ↗

Rational Identification of a Colorectal Cancer Targeting Peptide through Phage DisplaySemantic proximity Read ↗

Prognostic significance of Claudin18.2 expression in patients with gastric cancer: Insights from original research and meta-analysisSemantic proximity Read ↗

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapySemantic proximity Read ↗

Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancerSemantic proximity Read ↗

Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1Semantic proximity Read ↗

Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity TargetingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.